Journal of Ginseng Research

The Korean Society of Ginseng (고려인삼학회)
권호 표지
DOI QR코드

DOI QR Code

Korean Red Ginseng: Qualitative and Quantitative Benefits on Helicobacter pylori Infection

  • Chung, Jun-Won (Department of Gastroenterology, Gachon Graduate School of Medicine Gil Medical Center) ;
  • Kim, Yoon-Jae (Department of Gastroenterology, Gachon Graduate School of Medicine Gil Medical Center) ;
  • Lee, So-Jung (Department of Gastroenterology, Gachon Graduate School of Medicine Gil Medical Center) ;
  • Hahm, Ki-Baik (Department of Gastroenterology, Gachon Graduate School of Medicine Gil Medical Center)
  • Received : 2010.03.30
  • Accepted : 2010.04.19
  • Published : 2010.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Ginseng has been reported to reduce the risk of cancer in diverse organs, including the lip, oral cavity, pharynx, larynx, esophagus, lung, liver, pancreas, ovary, colon, rectum, and stomach, as demonstrated in clinical and epidemiological studies. studies, base on which findings, Panax ginseng has been classified as a "non-organ-specific cancer preventive." However, the recent keen interest in traditional medicinal herbs has been frequently questioned, about exact mode of action and the use of panaceic compounds has been a prime issue discussed in terms of complementary and alternative medicine. Several in vitro and in vivo studies have shown the mitigating effects of Korean red ginseng on Helicobacter pylori (H. pylori)-associated atrophic changes and carcinogenesis; However, evidence-based medicine, consisting of large-scale or well designed clinical studies, is still warranted whether Korean red ginseng is to be recognized as an essential therapeutic strategy regarding a "H. pylori-associated gastric cancer preventive." Specifically, comprehensive clinical trials of Korean red ginseng are needed to demonstrate that mucosal regeneration in patients with atrophic gastritis is feasible using Korean red ginseng supplements after the eradication of H. pylori infection. Ginseng is a good example of a natural herb and its ubiquitous properties may include the reduction or delay of inflammation carcinogenesis. Korean red ginseng contains ample amounts of active ginsenosides and we have demonstrated their effects in in vitro and in vivo studies with positive outcomes. In this review, the quantitative and qualitative benefits of Korean red ginseng in the treatment of H. pylori infection are described.

Keywords

References

  1. Dorer MS, Talarico S, Salama NR. Helicobacter pylori’s unconventional role in health and disease. PLoS Pathog 2009;5:e1000544. https://doi.org/10.1371/journal.ppat.1000544
  2. McNamara D, El-Omar E. Helicobacter pylori infection and the pathogenesis of gastric cancer: a paradigm for host-bacterial interactions. Dig Liver Dis 2008;40:504-509. https://doi.org/10.1016/j.dld.2008.02.031
  3. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789. https://doi.org/10.1056/NEJMoa001999
  4. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002;347:1175-1186. https://doi.org/10.1056/NEJMra020542
  5. Correa P, Houghton J. Carcinogenesis of Helicobacter pylori. Gastroenterology 2007;133:659-672. https://doi.org/10.1053/j.gastro.2007.06.026
  6. Suzuki H, Hibi T, Marshall BJ. Helicobacter pylori: present status and future prospects in Japan. J Gastroenterol 2007;42:1-15.
  7. Weck MN, Brenner H. Association of Helicobacter pylori infection with chronic atrophic gastritis: Meta-analyses according to type of disease definition. Int J Cancer 2008;123:874-881. https://doi.org/10.1002/ijc.23539
  8. Suzuki H, Marshall BJ, Hibi T. Overview: Helicobacter pylori and extragastric disease. Int J Hematol 2006;84:291-300. https://doi.org/10.1532/IJH97.06180
  9. Prelipcean CC, Mihai C, Gogalniceanu P, Mitrica D, Drug VL, Stanciu C. Extragastric manifestations of Helicobacter pylori infection. Rev Med Chir Soc Med Nat Iasi 2007;111:575-583.
  10. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, Oguma K, Okada H, Shiratori Y. The effect of eradicating Helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 2005;100:1037-1042. https://doi.org/10.1111/j.1572-0241.2005.41384.x
  11. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006;72:1605-1621. https://doi.org/10.1016/j.bcp.2006.06.029
  12. Lee DH, Hahm KB. Inflammatory cytokine gene polymorphisms and gastric cancer. J Gastroenterol Hepatol 2008;23:1470-1472. https://doi.org/10.1111/j.1440-1746.2008.05563.x
  13. Kato M, Asaka M, Nakamura T, Azuma T, Tomita E, Kamoshida T, Sato K, Inaba T, Shirasaka D, Okamoto S, et al. Helicobacter pylori eradication prevents the development of gastric cancer – results of a long-term retrospective study in Japan. Aliment Pharmacol Ther Symp Series 2006;24:203-206.
  14. Sung JJ, Lin SR, Ching JY, Zhou LY, To KF, Wang RT, Leung WK, Ng EK, Lau JY, Lee YT, et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection:a prospective, randomized study. Gastroenterology 2000;119:7-14. https://doi.org/10.1053/gast.2000.8550
  15. Park S, Kim WS, Choi UJ, Han SU, Kim YS, Kim YB, Chung MH, Nam KT, Kim DY, Cho SW, et al. Amelioration of oxidative stress with ensuing inflammation contributes to chemoprevention of H. pylori-associated gastric carcinogenesis. Antioxid Redox Signal 2004;6:549-560. https://doi.org/10.1089/152308604773934305
  16. Malfertheiner P, Megraud F, O’Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgat G; European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-180.
  17. McLoughlin R, Racz I, Buckley M, O’Connor HJ, O’Morain C. Therapy of Helicobacter pylori. Helicobacter 2004;9 Suppl 1:42-48. https://doi.org/10.1111/j.1083-4389.2004.00251.x
  18. Malfertheiner P, Megraud F, O’Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-781. https://doi.org/10.1136/gut.2006.101634
  19. Gaby AR. Helicobacter pylori eradication: are there alternatives to antibiotics? Altern Med Rev 2001;6:355-366.
  20. Carson CF, Riley TV. Non-antibiotic therapies for infectious diseases. Commun Dis Intell 2003;27 Suppl:S143-S146.
  21. Lee SY, Shin YW, Hahm KB. Phytoceuticals: mighty but ignored weapons against Helicobacter pylori infection. J Dig Dis 2008;9:129-139. https://doi.org/10.1111/j.1751-2980.2008.00334.x
  22. Kim MN, Kim N, Lee SH, Park YS, Hwang JH, Kim JW, Jeong SH, Lee DH, Kim JS, Jung HC, et al. The effects of probiotics on PPI-triple therapy for Helicobacter pylori eradication. Helicobacter 2008;13:261-268. https://doi.org/10.1111/j.1523-5378.2008.00601.x
  23. Sachdeva A, Nagpal J. Meta-analysis: efficacy of bovine lactoferrin in Helicobacter pylori eradication. Aliment Pharmacol Ther 2009;29:720-730. https://doi.org/10.1111/j.1365-2036.2009.03934.x
  24. Sezikli M, Cetinkaya ZA, Sezikli H, Guzelbulut F, Tiftikci A, Ince AT, Gokden Y, Yasar B, Atalay S, Kurdas OO. Oxidative stress in Helicobacter pylori infection: does supplementation with vitamins C and E increase the eradication rate? Helicobacter 2009;14:280-285. https://doi.org/10.1111/j.1523-5378.2009.00686.x
  25. Chuang CH, Sheu BS, Huang AH, Yang HB, Wu JJ. Vitamin C and E supplements to lansoprazole-amoxicillin-metronidazole triple therapy may reduce the eradication rate of metronidazole-susceptible Helicobacter pylori infection. Helicobacter 2002;7:310-316. https://doi.org/10.1046/j.1523-5378.2002.00095.x
  26. Gotteland M, Brunser O, Cruchet S. Systematic review: are probiotics useful in controlling gastric colonization by Helicobacter pylori? Aliment Pharmacol Ther 2006;23:1077-1086. https://doi.org/10.1111/j.1365-2036.2006.02868.x
  27. Park S, Yeo M, Jin JH, Lee KM, Jung JY, Choue R, Cho SW, Hahm KB. Rescue of Helicobacter pylori-induced cytotoxicity by red ginseng. Dig Dis Sci 2005;50:1218-1227. https://doi.org/10.1007/s10620-005-2763-x
  28. Lee H, Kho HS, Chung JW, Chung SC, Kim YK. Volatile sulfur compounds produced by Helicobacter pylori. J Clin Gastroenterol 2006;40:421-426. https://doi.org/10.1097/00004836-200605000-00011
  29. Lee WM, Kim SD, Kim KS, Song YB, Kwak YS, Cho JY, Park HJ, Oh JW, Rhee MH. Protopanaxadiol modulates LPS-induced inflammatory activity in murine macrophage RAW264.7 cells. J Ginseng Res 2006;30:181-187. https://doi.org/10.5142/JGR.2006.30.4.181
  30. Kim EH, Park JD, Pyo SN, Rhee DK. Effects of non-saponin red ginseng components on multi-drug resistance. J Ginseng Res 2007;31:74-78. https://doi.org/10.5142/JGR.2007.31.2.074
  31. Park S, Yeo M, Jin JH, Lee KM, Kim SS, Choi SY, Hahm KB. Inhibitory activities and attenuated expressions of 5-LOX with red ginseng in Helicobacter pylori-infected gastric epithelial cells. Dig Dis Sci 2007;52:973-982. https://doi.org/10.1007/s10620-006-9440-6
  32. Joo HK, Lee SK, Kim HS, Song YJ, Kang G, Park JB, Lee KH, Cho EJ, Lee JH, Seong IW, et al. Korean red ginseng extract inhibits tumor necrosis factor-alpha-induced monocyte adhesion in the human endothelial cells. J Ginseng Res 2008;32:244-249. https://doi.org/10.5142/JGR.2008.32.3.244
  33. Chung JW, Hahm KB. Rejuvenation of atrophic gastritis in the elderly. J Gastroenterol Hepatol 2010;25:434-435. https://doi.org/10.1111/j.1440-1746.2010.06251.x
  34. You WC, Zhang L, Gail MH, Chang YS, Liu WD, Ma JL, Li JY, Jin ML, Hu YR, Yang CS, et al. Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C, and other risk factors. J Natl Cancer Inst 2000;92:1607-1612. https://doi.org/10.1093/jnci/92.19.1607
  35. Leung WK, Lin SR, Ching JY, To KF, Ng EK, Chan FK, Lau JY, Sung JJ. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004;53:1244-1249. https://doi.org/10.1136/gut.2003.034629
  36. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004;291:187-194. https://doi.org/10.1001/jama.291.2.187
  37. Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, Correa P. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005;54:1536-1540. https://doi.org/10.1136/gut.2005.072009
  38. Takenaka R, Okada H, Kato J, Makidono C, Hori S, Kawahara Y, Miyoshi M, Yumoto E, Imagawa A, Toyokawa T, et al. Helicobacter pylori eradication reduced the incidence of gastric cancer, especially of the intestinal type. Aliment Pharmacol Ther 2007;25:805-812. https://doi.org/10.1111/j.1365-2036.2007.03268.x
  39. Kabir S. Effect of Helicobacter pylori eradication on incidence of gastric cancer in human and animal models: underlying biochemical and molecular events. Helicobacter 2009;14:159-171. https://doi.org/10.1111/j.1523-5378.2009.00677.x
  40. Fukase K, Kato M, Kikuchi S, Inoue K, Uemura N, Okamoto S, Terao S, Amagai K, Hayashi S, Asaka M, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resectionof early gastric cancer: an open-label, randomised controlled trial. Lancet 2008;372:392-397. https://doi.org/10.1016/S0140-6736(08)61159-9
  41. Tangerman A. Halitosis in medicine: a review. Int Dent J 2002;52 Suppl 3:201-206. https://doi.org/10.1002/j.1875-595X.2002.tb00925.x
  42. Porter SR, Scully C. Oral malodour (halitosis). BMJ 2006;333:632-635. https://doi.org/10.1136/bmj.38954.631968.AE
  43. Feller L, Blignaut E. Halitosis: a review. SADJ 2005;60:17-19.
  44. Hoshi K, Yamano Y, Mitsunaga A, Shimizu S, Kagawa J, Ogiuchi H. Gastrointestinal diseases and halitosis: association of gastric Helicobacter pylori infection. Int Dent J 2002;52 Suppl 3:207-211. https://doi.org/10.1002/j.1875-595X.2002.tb00926.x
  45. Tiomny E, Arber N, Moshkowitz M, Peled Y, Gilat T. Halitosis and Helicobacter pylori. A possible link? J Clin Gastroenterol 1992;15:236-237. https://doi.org/10.1097/00004836-199210000-00013
  46. Katsinelos P, Tziomalos K, Chatzimavroudis G, Vasiliadis T, Katsinelos T, Pilpilidis I, Triantafillidis I, Paroutoglou G, Papaziogas B. Eradication therapy in Helicobacter pylori-positive patients with halitosis: long-term outcome. Med Princ Pract 2007;16:119-123. https://doi.org/10.1159/000098364
  47. Lee JS, Kwon KA, Jung HS, Kim JH, Hahm KB. Korea red ginseng on Helicobacter pylori-induced halitosis: newer therapeutic strategy and a plausible mechanism. Digestion 2009;80:192-199. https://doi.org/10.1159/000229997
  48. Yoo SH, Jung HS, Sohn WS, Kim BH, Ku BH, Kim YS, Park SW, Hahm KB. Volatile sulfur compounds as a predictor for esophagogastroduodenal mucosal injury. Gut Liver 2008;2:113-118. https://doi.org/10.5009/gnl.2008.2.2.113
  49. Kim DK, Lee JA, Kim YB, Lee KM, Hahm KB. A randomized controlled trial assessing Korea red ginseng treatment of Helicobacter pylori-associated chronic gastritis.Korean J Med 2007;72:20-28.
  50. Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol Cancer Res 2006;4:221-233. https://doi.org/10.1158/1541-7786.MCR-05-0261
  51. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007;121:2381-2386. https://doi.org/10.1002/ijc.23192
  52. Moss SF, Blaser MJ. Mechanisms of disease: Inflammation and the origins of cancer. Nat Clin Pract Oncol 2005;2:90-97. https://doi.org/10.1038/ncponc0081
  53. Ono M. Molecular links between tumor angiogenesis and inflammation: inflammatory stimuli of macrophages and cancer cells as targets for therapeutic strategy. Cancer Sci 2008;99:1501-1506. https://doi.org/10.1111/j.1349-7006.2008.00853.x
  54. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-545. https://doi.org/10.1016/S0140-6736(00)04046-0
  55. Bode AM, Dong Z. Cancer prevention research - then and now. Nat Rev Cancer 2009;9:508-516. https://doi.org/10.1038/nrc2646
  56. Ohshima H, Tazawa H, Sylla BS, Sawa T. Prevention of human cancer by modulation of chronic inflammatory processes. Mutat Res 2005;591:110-122. https://doi.org/10.1016/j.mrfmmm.2005.03.030
  57. Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:71-78. https://doi.org/10.1038/nrc1256
  58. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003;3:276-285. https://doi.org/10.1038/nrc1046
  59. Suzuki M, Suzuki H, Hibi T. Proton pump inhibitors and gastritis. J Clin Biochem Nutr 2008;42:71-75. https://doi.org/10.3164/jcbn.2008012
  60. Nakajima N, Ito Y, Yokoyama K, Uno A, Kinukawa N, Nemoto N, Moriyama M. The Expression of Murine Double Minute 2 (MDM2) on Helicobacter pylori-infected intestinal metaplasia and gastric cancer. J Clin Biochem Nutr 2009;44:196-202. https://doi.org/10.3164/jcbn.08-254
  61. Odashima S, Ohta T, Kohno H, Matsuda T, Kitagawa I, Abe H, Arichi S. Control of phenotypic expression of cultured B16 melanoma cells by plant glycosides. Cancer Res 1985;45:2781-2784.
  62. Keum YS, Park KK, Lee JM, Chun KS, Park JH, Lee SK, Kwon H, Surh YJ. Antioxidant and anti-tumor promoting activities of the methanol extract of heat-processed ginseng.Cancer Lett 2000;150:41-48. https://doi.org/10.1016/S0304-3835(99)00369-9
  63. Yun TK. Panax ginseng--a non-organ-specific cancer preventive?Lancet Oncol 2001;2:49-55. https://doi.org/10.1016/S1470-2045(00)00196-0
  64. Lee JH, Cheon JH, Park MJ, Kim N, Lee DH, Kim JM, Kim JS, Jung HC, Song IS. The trend of eradication rates of second-line quadruple therapy containing metronidazole for Helicobacter pylori infection: an analysis of recent eight years. Korean J Gastroenterol 2005;46:94-98.
  65. Houben MH, van de Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999;13:1047-1055. https://doi.org/10.1046/j.1365-2036.1999.00555.x
  66. Gisbert JP, Pajares JM. Review article: Helicobacter pylori “rescue” regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002;16:1047-1057. https://doi.org/10.1046/j.1365-2036.2002.01276.x
  67. Zojaji H, Talaie R, Mirsattari D, Haghazali M, Molaei M, Mohsenian N, Derakhshan F, Zali MR. The efficacy of Helicobacter pylori eradication regimen with and without vitamin C supplementation. Dig Liver Dis 2009;41:644-647. https://doi.org/10.1016/j.dld.2008.09.008
  68. Lee SJ, Park JY, Choi KS, Ock CY, Hong KS, Kim YJ, Chung JW, Hahm KB. Efficacy of Korean red ginseng supplementation on eradication rate and gastric volatile sulfur compound levels after Helicobacter pylori eradictiontherapy. J Ginseng Res 2010;34:122-131. https://doi.org/10.5142/jgr.2010.34.2.122
  69. Pounder RE, Ng D. The prevalence of Helicobacter pylori infection in different countries. Aliment Pharmacol Ther 1995;9 Suppl 2:33-39.
  70. Yim JY, Kim N, Choi SH, Kim YS, Cho KR, Kim SS, Seo GS, Kim HU, Baik GH, Sin CS, et al. Seroprevalence of Helicobacter pylori in South Korea. Helicobacter 2007;12:333-340. https://doi.org/10.1111/j.1523-5378.2007.00504.x

Cited by

  1. Ginseng in Traditional Herbal Prescriptions vol.36, pp.3, 2012, https://doi.org/10.5142/jgr.2012.36.3.225
  2. Antimicrobial activities of Asian ginseng, American ginseng, and notoginseng vol.34, pp.6, 2010, https://doi.org/10.1002/ptr.6605